Skip to navigation bar Skip to breadcrumbs Skip to page content Skip to comments area
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A
You are here: HomePublic Comments and NominationsOpportunity for Public CommentDraft Evidence Review : Draft Evidence Review

Draft Evidence Review

Draft Evidence Review for Menopausal Hormone Therapy: Primary Prevention of Chronic Conditions

This opportunity for public comment expires on June 12, 2017 at 8:00 PM EST

Note: This is a Draft Evidence Review. This draft is distributed solely for the purpose of receiving public input. It has not been disseminated otherwise by the USPSTF. The final Evidence Review will be used to inform the USPSTF Recommendation Statement on this topic.

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Send Us Your Comments

In an effort to maintain a high level of transparency in our methods, we open our draft Evidence Reviews to a public comment period before we publish the final version.

Leave a Comment >>

Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: An Evidence Review for the U.S. Preventive Services Task Force (PDF File, 1.4 MB; PDF Help)

Persons using assistive technology may not be able to fully access information in this PDF file. For assistance, contact Lisa Nicolella at (301) 427-1906 or lisa.nicolella@ahrq.hhs.gov.

Current as of: May 2017

Internet Citation: Draft Evidence Review: Menopausal Hormone Therapy: Primary Prevention of Chronic Conditions . U.S. Preventive Services Task Force. May 2017.
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/menopausal-hormone-therapy-preventive-medication1

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857